{
  "authorized_claims": [
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "DHA contributes to the maintenance of normal brain function.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2): claim may be used only for food which contains at least 40 mg of DHA per 100 g and per 100 kcal; consumer informed that the beneficial effect is obtained with a daily intake of 250 mg of DHA"
    },
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "DHA contributes to the maintenance of normal vision.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2): claim may be used only for food which contains at least 40 mg of DHA per 100 g and per 100 kcal; consumer informed that the beneficial effect is obtained with a daily intake of 250 mg of DHA"
    },
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "Maternal intake of DHA contributes to normal brain development of the foetus and breastfed infants.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 14(1)(b): claim may only be used for food which provides a daily intake of at least 200 mg DHA in addition to the recommended daily intake of n-3 fatty acids for adults (250 mg DHA and EPA); claim shall be made available only for foods intended for pregnant and lactating women"
    },
    {
      "market": "ANVISA",
      "framework_reference": "IN 28/2018 Anexo V alegação funcional",
      "claim_verbatim": "Os ácidos graxos ômega 3 EPA e DHA auxiliam na redução dos triglicerídeos.",
      "authorization_date": "2018",
      "conditions": "IN 28/2018 Anexo V: alegação restrita a suplementos que forneçam ao menos 1.500 mg de EPA + DHA por dia"
    }
  ],
  "slug": "dha",
  "name": "DHA (Docosahexaenoic Acid · Pure / High-DHA Formulations)",
  "alternate_names": [
    "Docosahexaenoic acid",
    "Pure DHA",
    "High-DHA omega-3",
    "Algal DHA-only formulation"
  ],
  "mechanism": [
    "Omega-3 C22:6 PUFA · highly enriched in retinal photoreceptors and synaptic neuronal membranes",
    "Substrate for D-series Resolvins / Protectins / Maresins (SPM family)",
    "Membrane phospholipid integration in brain phosphatidylethanolamine pools",
    "Maternal-foetal placental transfer for foetal brain development (basis for EFSA art 14(1)(b) maternal DHA claim)"
  ],
  "target": [
    "Synaptic membrane DHA pool",
    "Retinal photoreceptor DHA",
    "Maternal DHA reserves and foetal brain DHA accretion (third trimester window)"
  ],
  "use_case": [
    "maternal supplementation for foetal brain development (200 mg DHA/day above general omega-3 RDA per EFSA art 14(1)(b))",
    "visual maintenance and cognitive maintenance per EFSA Reg 432/2012 at 250 mg DHA/day",
    "vegan / vegetarian DHA-only adequacy via algal-sourced product"
  ],
  "body_system": [
    "NEURO",
    "VISION",
    "REPRODUCTIVE"
  ],
  "evidence_tier": "A",
  "evidence_anchor_pmid_count": 1,
  "dosage_range": "200 mg DHA/day in addition to the 250 mg EPA+DHA general RDA — required for the EFSA art 14(1)(b) maternal DHA claim. For age-related cognitive decline the DHA supplementation evidence is mixed: Balachandar 2020 PMID 32060571 European Journal of Clinical Pharmacology systematic review and meta-analysis of 10 RCT (n = 2,327 elderly) found minimal or no pooled incremental effects on memory, attention, working memory or executive function · honest framing: DHA cognitive maintenance under EFSA claim is structural maintenance, not cognitive restoration in age-related decline",
  "safety_notes": "Excellent safety profile within recommended supplementation ranges; very-high-dose DHA (> 5 g/day) is not advised without clinician oversight; vegan-DHA products are typically marine-algae-based and avoid fish allergens",
  "regulatory": {
    "fda": "GRAS · DSHEA dietary supplement · qualified health claims under the omega-3 framework when EPA+DHA blend threshold met",
    "efsa": "Authorized claims Reg 432/2012 (brain function, vision) when DHA per-serving threshold reached + art 14(1)(b) maternal DHA claim",
    "anvisa": "RDC 243/2018 dietary supplement · IN 28/2018 Anexo V alegação funcional verbatim: \"Os ácidos graxos ômega 3 EPA e DHA auxiliam na redução dos triglicerídeos.\" (≥ 1.500 mg EPA+DHA/dia)"
  },
  "ingredient_hub_url": "https://asxan.ai/ingredients/dha/",
  "related_goal_slugs": [
    "cognitive-support",
    "eye-protection",
    "reproductive-health"
  ],
  "related_lifestyle_slugs": [
    "pregnancy",
    "plant-based",
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-06-04",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-04",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}